Epidemiology and risk factors for infections due to AmpC Β-lactamase-producing Escherichia Coli

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 899-904

  Pascual, Vanesa ^a   Ortiz, Gabriel ^b   Simó, Maria ^c   Alonso, Noemí ^b,d,e   Garcia, Maria Consol ^f   Xercavins, Mariona ^c   Rivera, Alba ^b   Morera, Maria Antonia ^c   Miró, Elisenda ^b,e   Espejo, Elena ^f   Navarro, Ferran ^b,d,e   Gurguí, Mercé ^b,d,e   Pérez, Josefa ^c   Rodríguez Carballeira, Mónica ^a   Garau, Javier ^a   Calbo, Esther ^a,g  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c Catlab   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Brain   (Spain)

^g UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Ampc lactamases; Cephalosporins resistance; E. coli

Indexed keywords

BETA LACTAMASE AMPC; CEPHALOSPORIN DERIVATIVE; QUINOLONE DERIVATIVE; AMPC BETA-LACTAMASES; BACTERIAL PROTEIN; BETA LACTAMASE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG USE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; GENE SEQUENCE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PLASMID; POLYMERASE CHAIN REACTION; PREVALENCE; PROMOTER REGION; PROSPECTIVE STUDY; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; BIOSYNTHESIS; CROSS-SECTIONAL STUDY; DNA SEQUENCE; ENZYMOLOGY; ESCHERICHIA COLI INFECTIONS; GENE EXPRESSION PROFILING; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL PROTEINS; BETA-LACTAMASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; MULTIPLEX POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84928178413     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku468     Document Type: Article

References (41)

1. Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-7.
2. Vallés J, Calbo E, Anoro E et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008; 56:27-34.
3. Paterson DL, Bonomo RA. Extended-spectrum b-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
4. Calbo E, Romaní V, Xercavins M et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extendedspectrum b-lactamases. J Antimicrob Chemother 2006; 57:780-3.
5. Denisuik AJ, Lagacé-Wiens PR, Pitout JD et al. Molecular epidemiology of extended-spectrum b-lactamase-, AmpC b-lactamase-and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 2013; 68: Suppl 1: i57-65.
6. Jacoby GA. AmpC b-lactamases. Clin Microbiol Rev 2009; 22:161-82.
7. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2010; 65: Suppl 3: iii25-33.
8. Potz NA, Hope R, Warner M et al. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 2006; 58:320-6.
9. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59:165-74.
10. Jaurin B, Grundström T, Edlund T et al. TheE. coli b-lactamase attenuator mediates growth rate-dependent regulation. Nature 1981; 290:221-5.
11. Jaurin B, Grundström T, Normark S. Sequence elements determining ampC promoter strength in E. coli. EMBO J 1982; 1:875-81.
12. Mammeri H1, Nordmann P, Berkani A et al. Contribution of extendedspectrum AmpC (ESAC) b-lactamases to carbapenem resistance in Escherichia coli. FEMS Microbiol Lett 2008; 282:238-40.
13. Martínez-Martínez L, Pascual A, Hernández-Allés S et al. Roles of b-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999; 43:1669-73.
14. Rodríguez-Baño J, Miró E, Villar M et al. Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC b-lactamases. J Infect 2012; 64:176-83.
15. Sidjabat HE, Paterson DL, Qureshi ZA et al. Clinical features and molecular epidemiology of CMY-type b-lactamase-producing Escherichia coli. Clin Infect Dis 2009; 48:739-44.
16. Simner PJ, Zhanel GG, Pitout J et al. Prevalence and characterization of extended-spectrum b-lactamase-and AmpC b-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. Diagn Microbiol Infect Dis 2011; 69:326-34.
17. Choi SH, Lee JE, Park SJ et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC b-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008; 52:995-1000.
18. Matsumura Y, Nagao M, Iguchi M et al. Molecular and clinical characterization of plasmid-mediated AmpC b-lactamase-producing Escherichia coli bacteraemia: a comparison with extended-spectrum b-lactamaseproducing and non-resistant E. coli bacteraemia. Clin Microbiol Infect 2013; 19:161-8.
19. Park YS, Yoo S, Seo MR et al. Risk factors and clinical features of infections caused by plasmid-mediated AmpC b-lactamase-producing Enterobacteriaceae. Int J Antimicrob Agents 2009; 34:38-43.
20. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
22. Bauer AW, Kirby WM, Sherris JC et al. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45:493-6.
23. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
24. Navarro F, Calvo J, Cantón Ret al. Deteccion fenotipica de mecanismos de resistencia en microorganismos gramnegativos. Enferm Infecc Microbiol Clin 2011; 29:524-34.
25. Mirelis B, Rivera A, Miró E et al. A simple phenotypic method for differentiation between acquired and chromosomal AmpC b-lactamases in Escherichia coli. Enferm Infecc Microbiol Clin 2006; 24:370-2.
26. Pérez-Pérez FJ, Hanson ND et al. Detection of plasmid-mediated AmpC b-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40:2153-62.
27. Miró E, Aguero J, Larrosa MN et al. Prevalence and molecular epidemiology of acquired AmpC b-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 2013; 32:253-9.
28. Haldorsen B, Aasnaes B, Dahl KH et al. The AmpC phenotype in Norwegian clinical isolates of Escherichia coli is associated with an acquired ISEcp1-like ampC element or hyperproduction of the endogenous AmpC. J Antimicrob Chemother 2008; 62:694-702.
29. Mata C, Miró E, Rivera A et al. Prevalence of acquired AmpC b-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin Microbiol Infect 2010; 16:472-6.
30. Ding H, Yang Y, Lu Q et al. The prevalence of plasmid-mediated AmpC b-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children's hospitals in China. Eur J Clin Microbiol Infect Dis 2008; 27:915-21.
31. Tofteland S, Dahl KH, Aasnæs B et al. A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical Escherichia coli and Klebsiella spp. isolates. Scand J Infect Dis 2012; 44:927-33.
32. Li Y, Li Q, Du Y et al. Prevalence of plasmid-mediated AmpC b-lactamases in a Chinese university hospital from 2003 to 2005: first report of CMY-2-type AmpC b-lactamase resistance in China. J Clin Microbiol 2008; 46:1317-21.
33. Pitout JD, Gregson DB, Church DL et al. Population-based laboratory surveillance for AmpC b-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis 2007; 13:443-8.
34. Rodríguez-Baño J, Oteo J, Ortega A et al. Epidemiological and clinical complexity of amoxicillin-clavulanate-resistant Escherichia coli. J Clin Microbiol 2013; 51:2414-7.
35. Pai H, Kang CI, Byeon JH et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-b-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:3720-8.
36. Lee CH, Su LH, Li CC et al. Microbiologic and clinical implications of bacteremia due to extended-spectrum-b-lactamase-producing Klebsiella pneumoniae with or without plasmid-mediated AmpC b-lactamase DHA-1. Antimicrob Agents Chemother 2010; 54:5395-8.
37. Paltansing S1, Kraakman ME, Ras JM et al. Characterization of fluoroquinolone and cephalosporin resistance mechanisms in Enterobacteriaceae isolated in a Dutch teaching hospital reveals the presence of an Escherichia coli ST131 clone with a specific mutation in parE. J Antimicrob Chemother 2013; 68:40-5.
38. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6:629-40.
39. Doi Y, Park YS, Rivera JI et al. Community-associated extendedspectrum b-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56:641-8.
40. Ohana S, Leflon V, Ronco E et al. Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC b-lactamase in a teaching hospital admitting disabled patients. Antimicrob Agents Chemother 2005; 49:2095-7.
41. Tsui K, Wong SS, Lin LC et al. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type b-lactamases. J Microbiol Immunol Infect 2012; 45:193-9.